Services

testing neo-angiogenic potential

Angiogenesis, the formation of new blood vessels, is a physiological process that plays an essential role in several pathological disorders such as tumor growth, psoriasis or macular degeneration. On the other hand, neo-angiogenesis is involved in tissue regeneration. Therefore, the search for novel drugs that inhibit or stimulate neo-angiogenesis and counteract this imbalance in blood vessel formation resulting in severe diseases is of ever-increasing importance. Evercyte has established relevant and standardizable in vitro model systems that can mimic neo-angiogenesis in vivo and will drive the search for novel drugs.

General information

In vitro model: Evercyte has generated telomerized human umbilical vein endothelial cells (HUVEC/TERT2) that can be grown without limitation while maintaining a primary-like phenotype.

Assay set-up: HUVEC/TERT2 cells are seeded onto matrigel matrix and the formation of tubule-like structures is monitored. Additionally, HUVEC/TERT2 cells can be grown as 3D spheroids. Treatment of these spheroids with vascular endothelial growth factor (VEGF) leads to formation of sprouts indicating induction of neo-angiogenesis. The length and number of sprouts that are formed allows the identification of compounds with pro- or anti-angiogenic activities. Fast screening of compounds for neo-angiogenic potential is done by seeding HUVEC/TERT2 cells into multi-well plates followed by treatment with test compounds and measurement of cellular proliferation.
Timelines:
depending on the bioassay, the number of samples,  replicates and concentrations tested, it takes between 2 and 6 weeks to deliver results.

Testing neo-angiogenic potential of compounds

sprout formation from endothelial spheroids

When human umbilical vein endothelial cells (HUVEC/TERT2) are grown in hanging drops, they form 3D spheroids that can be embedded into a collagen matrix. Treatment of these spheroids with vascular endothelial growth factor (VEGF) induces the formation of sprouts. Concommitant cultivation in the presence of VEGF and Cyclosporin A (CSA) significantly reduces sprout formation in a concentration-dependent manner.

Testing endothelial cell proliferation

2D proliferation assay

Telomerized human endothelial cells (HUVEC/TERT2) are seeded into multi-well plates followed by treatment with vascular endothelial growth factor (VEGF) with / without anti-angiogenic agents ranibizumab (Lucentis®) and bevacizumab (Avastin®). Measurement of cellular proliferation demonstrates that Lucentis and Avastin inhibit VEGF induced proliferation in a concentration dependent manner.

Print Friendly, PDF & Email
get in contact

Related Services

establishment of stable cell lines for proudction of extracellular vesicles

read more

WJ-MSC/TERT273

Wharton´s Jelly derived mesenchymal stem cells

read more

MSCs for production of clinical grade extracellular vesicles

send us specific request

Customer Reviews

“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”

 

Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.

"Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform.  We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed."

Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.

all about our
EV cell factories

read more

human telomerized endothelial cells

HUVEC/TERT2 cells can be grown as 3D spheroids and form sprouts upon treatment with vascular endothelial growth factor

read more

Related Services

testing extracellular vesicles / exosomes for neo-angiogenic properties using 2D or 3D in vitro bioassays

specific request

Customer Reviews

“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”

 

Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.

"Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform.  We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed."

Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.

Print Friendly, PDF & Email